Roche Enters $15 Billion Drug Development Deal With China's Hansoh

Key Facts

1Swiss drugmaker Roche has partnered with China's Hansoh in a deal that could exceed $15 billion.

2Roche will assume responsibility outside of China, Hong Kong, Macau, and Taiwan following the completion of early-stage clinical trials.

Swiss drugmaker Roche has partnered with China's Hansoh in a deal that could exceed $15 billion. The Wall Street Journal reported that Roche will assume responsibility for the assets outside of China, Hong Kong, Macau, and Taiwan following the completion of early-stage clinical trials.

The collaboration aims to expand Roche's drug pipeline by leveraging Hansoh's clinical assets for global markets. RHHVF closed at $457.35 on October 16, 2026, having traded between a low of $449.42 and a high of $459.71 during that session.